Lipoproteins LDL versus HDL as nanocarriers to target either cancer cells or macrophages.

Fiche publication

Date publication

novembre 2020

Journal

JCI insight

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen , Dr LAGROST Laurent , Pr DENAT Franck , Dr COLLIN Bertrand , Pr LIRUSSI Frédéric , Pr SCHMITT Antonin , Dr BELLAYE Pierre-Simon , Dr WENDREMAIRE Maeva

Tous les auteurs :
Hadi T, Ramseyer C, Gautier T, Bellaye PS, Lopez T, Schmitt A, Sarah F, Yesylevskyy S, Minervini T, Douhard R, Dondaine L, Proukhnitzky L, Messaoudi S, Wendremaire M, Moreau M, Neiers F, Collin B, Denat F, Lagrost L, Garrido C, Lirussi F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33252359

Résumé

In this work, we have explored natural unmodified low- and high-density lipoproteins (LDL and HDL) as selective delivery vectors in colorectal cancer therapy. We show in vitro in cultured cells and in vivo (NanoSPECT/CT) in the CT-26 mice colorectal cancer model that LDLs are mainly taken up by cancer cells, while HDLs are preferentially taken up by macrophages. We loaded LDLs with cisplatin and HDLs with the heat shock protein-70 inhibitor AC1LINNC, turning them into a pair of "Trojan horses" delivering drugs selectively to their target cells as demonstrated in vitro in human colorectal cancer cells and macrophages, and in vivo. Coupling of the drugs to lipoproteins and stability was assessed by mass and raman spectrometry analysis. Cisplatin vectorized in LDLs led to better tumor growth suppression with strongly reduced adverse effects such as a renal or liver toxicity. AC1LINNC vectorized into HDLs induced a strong oxidative burst in macrophages and innate anti-cancer immune response. Cumulative anti-tumor effect was observed for both drug-loaded lipoproteins. Altogether, our data show that lipoproteins from patient's blood can be used as natural nanocarriers allowing cell specific targeting, paving the way toward more efficient, safer and personalized use of chemo-and immunotherapeutic drugs in cancer.